6 Appraisal Committee members and NICE project team
6.1 Appraisal Committee members
The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3-year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are 4 Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.
Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.
The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.
Dr Jane Adam (Chair)
Department of Diagnostic Radiology, St George's Hospital
Professor Iain Squire (Vice Chair)
Consultant Physician, University Hospitals of Leicester
Professor A E Ades
Professor of Public Health Science, Department of Community Based Medicine, University of Bristol
Professor Thanos Athanasiou
Professor of Cardiovascular Sciences and Cardiac Surgery and Consultant Cardiothoracic Surgeon, Imperial College London and Imperial College Healthcare NHS Trust
Dr Jeremy Braybrooke
Consultant Medical Oncologist, University Hospitals Bristol NHS Foundation Trust
Dr Gerardine Bryant
General Practitioner, Heartwood Medical Centre, Derbyshire
Dr Fiona Duncan
Clinical Nurse Specialist, Anaesthetic Department, Blackpool Victoria Hospital, Blackpool
Mr Andrew England
Lecturer in Medical Imaging, NIHR Fellow, University of Liverpool
Professor Jonathan Grigg
Professor of Paediatric Respiratory and Environmental Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University London
Dr Brian Hawkins
Chief Pharmacist, Cwm Taf Health Board, South Wales
Dr Peter Heywood
Consultant Neurologist, Frenchay Hospital
Dr Sharon Saint Lamont
Head of Quality and Innovation, North East Strategic Health Authority
Dr Ian Lewin
Consultant Endocrinologist, North Devon District Hospital
Dr Louise Longworth
Reader in Health Economics, HERG, Brunel University
Dr Anne McCune
Consultant Hepatologist, University Hospitals Bristol NHS Foundation Trust
Professor John McMurray
Professor of Medical Cardiology, University of Glasgow
Dr Alec Miners
Lecturer in Health Economics, London School of Hygiene and Tropical Medicine
Dr Mohit Misra
General Practitioner, Queen Elizabeth Hospital, London
Ms Sarah Parry
CNS Paediatric Pain Management, Bristol Royal Hospital for Children
Ms Pamela Rees
Lay Member
Dr Ann Richardson
Lay Member
Ms Ellen Rule
Programme Director, NHS Bristol
Mr Stephen Sharp
Senior Statistician, MRC Epidemiology Unit
Dr Peter Sims
General Practitioner, Devon
Dr Eldon Spackman
Research Fellow, Centre for Health Economics, University of York
Mr David Thomson
Lay Member
Dr John Watkins
Clinical Senior Lecturer/Consultant in Public Health Medicine, Cardiff University and National Public Health Service Wales
Dr Olivia Wu
Reader in Health Economics, University of Glasgow
6.2 NICE project team
Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.
Matthew Dyer
Technical Lead
Zoe Garrett
Technical Adviser
Bijal Joshi
Project Manager
Sources of evidence considered by the Committee
The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA Group:
-
Cummins E, Scott N, Rothnie K et al. Dapagliflozin for the treatment of type 2 diabetes. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen, November 2012.
The Decision Support Unit (DSU) reports for this appraisal are:
-
Davis S, Sheard J. A review of the Bristol‑Myers Squibb/AstraZeneca economic model on the cost-effectiveness of dapagliflozin, November 2012.
-
Davis S. Dapagliflozin for the treatment of type 2 diabetes: Additional analyses requested by the Committee following the second meeting, April 2013.
The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, Professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.
Manufacturers or sponsors:
-
Bristol Myers‑Squibb and AstraZeneca
Professional or specialist and patient or carer groups:
-
Black Ethnic Minority Diabetes Association
-
Diabetes UK
-
National Diabetes Nurses Consultant Group
-
Royal College of Nursing
-
Royal College of Pathologists
-
Royal College of Physicians
Other consultees:
-
Department of Health
-
Welsh Assembly Government
-
NHS Middlesbrough
Commentator organisations (did not provide written evidence and without the right of appeal):
-
Aberdeen HTA Group
-
Boehringer Ingelheim and Lilly UK (linagliptin)
-
Commissioning Support Appraisals Service
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Eli Lilly (exenatide, insulin)
-
Health Improvement Scotland
-
National Institute for Health Research Health Technology Assessment Programme
-
Novo Nordisk (insulin, liraglutide)
-
Pfizer (glipizide)
The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on dapagliflozin by attending Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.
-
Professor Eric Kilpatrick, Consultant in Chemical Pathology, Hull and East Yorkshire Hospitals NHS Trust nominated by organisation representing Royal College of Pathologists – clinical specialist (first Committee meeting)
-
Dr Peter Winocour, Consultant Physician and Clinical Director of Diabetes and Endocrine Services nominated by organisation representing Association of British Clinical Diabetologists (ABCD) and Royal College of Physicians (RCP) – clinical specialist (first Committee meeting)
-
Professor Jiten Vora, Consultant Physician and Endocrinologist nominated by organisation representing Royal College of Physicians and Association of British Clinical Diabetologists – clinical specialist (second Committee meeting)
-
Mrs Cathy Moulton, Clinical Advisor nominated by organisation representing Diabetes UK – patient expert
-
Ms Aderonke Kuti, Executive Director, nominated by organisation representing Black and Ethnic Minority Diabetes Association – patient expert
The following individuals were nominated as NHS Commissioning experts by the selected Commissioning Group allocated to this appraisal. They gave their expert/NHS commissioning personal view on dapagliflozin by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.
-
Ms Joanne Linton, Assistant Director Medicines Management selected by NHS Tees – NHS commissioning expert
-
Dr Victoria Ononeze, Public Health Specialist selected by NHS Tees – NHS commissioning expert
Representatives from the following manufacturers attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.
-
Bristol Myers‑Squibb and AstraZeneca (dapagliflozin)